Immunic appoints Jon Congleton, Mineralys CEO and ex-Teva exec, to Board

IMMUNIC, INC.

Jon Congleton appointed to Board as Class II director effective March 27, 2026; Board size increased from 8 to 9.
Congleton will chair Compensation Committee; received initial grant of options for 500,000 shares vesting over 3 years.
Congleton brings nearly 40 years of biopharma experience; currently CEO of Mineralys Therapeutics.
He previously led the U.S. launch of Copaxone at Teva and held senior roles at Impel NeuroPharma and Nivalis Therapeutics.
Appointment supports Immunic's transition to commercial stage for MS drug vidofludimus calcium.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.